GHRP-1

Summary

GHRP-1 is a synthetic growth-hormone-releasing heptapeptide; given intravenously to healthy short children and adolescents, it raised growth hormone within 15 to 30 minutes, while most children with pituitary insufficiency did not respond. · pmid:8279223

Growth hormone releasing peptides are on the World Anti-Doping Agency Prohibited List; after nasal use, GHRP-1 itself was not found in urine but six of its metabolites were, one for up to 27 hours. · pmid:25869809

Identity

PubChem CID 10350910: Growth hormone-releasing peptide 1, C51H62N12O7, 955.1 g/mol. · pubchem:10350910

CAS registry number 141925-59-9. · pubchem:10350910

IUPAC name: (2S)-6-amino-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-aminopropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-naphthalen-2-ylpropanoyl]amino]propanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanamide. · pubchem:10350910

Where the evidence actually sits

Proportion of the 2 claims about GHRP-1 standing at each tier. Community volume is shown on the Consensus tab beside this and is never averaged into it.

Living evidence history

2 resolved citations, oldest to newest, coloured by tier. Retractions and contradictions land here as they are recorded.

Structure

No structure representation on record. PepJunkie draws only what an authoritative record supplies; for a peptide that is the residue sequence, and none has been curated for GHRP-1 yet.

Dose evidence, rung by rung

No established safe human dose. Nothing on file establishes one. That is a statement about the evidence PepJunkie holds, not a promise about the molecule.

1. Approved-label dose · a resolved regulatory document names a labelled dose

   nothing resolved on this rung

2. Studied human doses · resolved human studies at the established tier

   nothing resolved on this rung

3. Observational evidence · resolved human data at the emerging tier: thin, or contested
   • Determination of growth hormone releasing peptides metabolites in human urine after nasal administration of GHRP-1, GHRP-2, GHRP-6, Hexarelin, and Ipamorelin. · pmid 25869809 · 2015
   • Growth hormone-releasing activity of growth hormone-releasing peptide-1 (a synthetic heptapeptide) in children and adolescents. · pmid 8279223 · 1993
4. Community-reported protocols · protocol propositions from distinct members, counted once per human

   nothing resolved on this rung

5. Preclinical evidence · resolved animal, cell or mechanistic work

   nothing resolved on this rung

2 resolved citations, 0 unresolved (an unresolved citation lends nothing). Community volume is its own rung and is never averaged into the evidence rungs.